Compare COSM & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COSM | BLRX |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4M | 17.1M |
| IPO Year | 2013 | 2011 |
| Metric | COSM | BLRX |
|---|---|---|
| Price | $0.50 | $3.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 616.4K | 28.9K |
| Earning Date | 11-17-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $59,792,819.00 | $12,735,000.00 |
| Revenue This Year | $28.14 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.69 | N/A |
| 52 Week Low | $0.28 | $2.30 |
| 52 Week High | $1.32 | $14.70 |
| Indicator | COSM | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.52 | 37.42 |
| Support Level | $0.41 | $3.14 |
| Resistance Level | $0.46 | $3.36 |
| Average True Range (ATR) | 0.05 | 0.20 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 37.87 | 0.00 |
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.